BUD APAC (01876) Announces First Three Quarters Results: Profit Attributable to Shareholders US$565 Million, Down 4.88% Year-on-Year
BUD APAC (01876) announced its results for the first nine months of 2026. During the period, the group recorded revenue of US$4.62 billion, down 3.7% year-on-year; profit attributable to equity holders of BUD APAC was US$565 million, down 4.88% year-on-year; normalized basic earnings per share were 4.75 US cents.
BUD APAC (01876) Announces First Three Quarters Results: Profit Attributable to Shareholders US$565 Million, Down 4.88% Year-on-Year
BUD APAC (01876) released its results for the first nine months of 2026, during which the Group recorded revenue of US$4.62 billion, down 3.7% year-on-year; profit attributable to equity holders of BUD APAC was US$565 million, down 4.88% year-on-year; normalized basic earnings per share were 4.75 US cents.
In the first nine months of 2026, total volume decreased by 4.9%, revenue decreased by 3.7%, while revenue per hectoliter increased by 1.2%. The Group's normalized EBITDA decreased by 13.2%, while the normalized EBITDA margin declined by 297 basis points.
In the third quarter of 2026, total volume decreased by 10.1%, affected by performance in China but partially offset by growth in India. Revenue decreased by 8.4%, while revenue per hectoliter increased by 1.9%, benefiting from a positive country mix. The Group's normalized EBITDA decreased by 22.9%, affected by the revenue performance in China, cost inflation, operating deleverage and lower other operating income.
Related Articles

CICC: Fed rate hikes not over, but no need to rush

ASCLETIS-B(01672): Oral small-molecule GLP-1 ASC30 achieved a placebo-adjusted HbA1c reduction of 1.7% at week 12 in a U.S. Phase II study in subjects with diabetes

INNOVENT BIO (01801) reported third-quarter product revenue exceeding RMB4.7 billion, up more than 40% year on year.
CICC: Fed rate hikes not over, but no need to rush

ASCLETIS-B(01672): Oral small-molecule GLP-1 ASC30 achieved a placebo-adjusted HbA1c reduction of 1.7% at week 12 in a U.S. Phase II study in subjects with diabetes

INNOVENT BIO (01801) reported third-quarter product revenue exceeding RMB4.7 billion, up more than 40% year on year.






